|
Narcolepsy
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
(3) The integrative analysis identified the CCR3 region where both a single methylation site and multiple single-nucleotide polymorphisms were found to be associated with the disease as a candidate region responsible for narcolepsy.
|
29425374 |
2018 |
|
Hypertensive disease
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Hypertension was associated with an increase in perivascular adipose tissue expression of the chemokine RANTES (relative quantification, 1.2 ± 0.2 vs. 3.5 ± 1.1; P < 0.05), which induced T-cell chemotaxis and vascular accumulation of T cells expressing the chemokine receptors CCR1, CCR3, and CCR5.
|
26873938 |
2016 |
|
Hodgkin Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CCR3 and CCR5 were highly expressed in T cells of HD involved but not of control lymph nodes.
|
11238088 |
2001 |
|
Dermatitis, Atopic
|
0.340 |
Biomarker
|
disease |
BEFREE |
CCR3 was detected weakly in epidermis of normal skin, while strong immunoreactivity for CCR3 was seen in epidermis of inflammatory skin lesions such as atopic dermatitis.
|
11240271 |
2001 |
|
Eczema
|
0.040 |
Biomarker
|
disease |
BEFREE |
CCR3 was detected weakly in epidermis of normal skin, while strong immunoreactivity for CCR3 was seen in epidermis of inflammatory skin lesions such as atopic dermatitis.
|
11240271 |
2001 |
|
Eosinophilia
|
0.070 |
Biomarker
|
disease |
BEFREE |
CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation.
|
11877470 |
2002 |
|
Eosinophilic disorder
|
0.060 |
Biomarker
|
group |
BEFREE |
CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation.
|
11877470 |
2002 |
|
Eosinophilia
|
0.070 |
Biomarker
|
disease |
BEFREE |
CCR3(+) eosinophils increased in the blood and lymph nodes of the transgenic mice by 50- and 300-fold, respectively.
|
12239140 |
2002 |
|
Blindness
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
CCR3 targeting might reduce vision loss due to AMD through early detection and therapeutic angioinhibition.
|
19525930 |
2009 |
|
Unspecified visual loss
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
CCR3 targeting might reduce vision loss due to AMD through early detection and therapeutic angioinhibition.
|
19525930 |
2009 |
|
Age related macular degeneration
|
0.030 |
Biomarker
|
disease |
BEFREE |
CCR3 targeting might reduce vision loss due to AMD through early detection and therapeutic angioinhibition.
|
19525930 |
2009 |
|
Lymphoma, T-Cell, Cutaneous
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CCR3(+) lymphocytes and IL-4 expression were observed in some cases of advanced CTCL.
|
20505746 |
2010 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CCR3, receptor of CCL28, was highly expressed in vascular endothelial cells in lung adenocarcinoma when examining by immunohistochemistry.
|
27250766 |
2016 |
|
Tumor Cell Invasion
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
CCR3 RNAi could effectively silence the expression of CCR3 mRNA and protein both <i>in vitro</i> and <i>in vivo</i>, thus promoting apoptosis of EOS and inhibiting its growth, migration and invasion.
|
28123492 |
2017 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CCR3 is the cognate receptor for major human eosinophil chemoattractants from the eotaxin family of proteins that are elevated in asthma and correlate with disease severity.
|
29423947 |
2018 |
|
Lymphoproliferative Disorders
|
0.010 |
AlteredExpression
|
group |
BEFREE |
CCR3 was expressed in 73% of cases of CD30+ lymphoproliferative disorders such as lymphomatoid papulosis and anaplastic large cell lymphoma.
|
31045236 |
2019 |
|
Lymphomatoid Papulosis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CCR3 was expressed in 73% of cases of CD30+ lymphoproliferative disorders such as lymphomatoid papulosis and anaplastic large cell lymphoma.
|
31045236 |
2019 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CCR3 was expressed in 73% of cases of CD30+ lymphoproliferative disorders such as lymphomatoid papulosis and anaplastic large cell lymphoma.
|
31045236 |
2019 |
|
Adult Anaplastic Large Cell Lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CCR3 was expressed in 73% of cases of CD30+ lymphoproliferative disorders such as lymphomatoid papulosis and anaplastic large cell lymphoma.
|
31045236 |
2019 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CCR3 was expressed in 73% of cases of CD30+ lymphoproliferative disorders such as lymphomatoid papulosis and anaplastic large cell lymphoma.
|
31045236 |
2019 |
|
Central Nervous System Infection
|
0.010 |
Biomarker
|
group |
BEFREE |
CCR3 appears critical in central nervous system infection.
|
9334732 |
1997 |
|
Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
A CCR3 receptor antagonist (SB 328437 [SB3]) was injected intraperitoneally 1 hour postinduction of colitis.
|
29968270 |
2018 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A CCL chemokine-derived peptide (CDIP-2) exerts anti-inflammatory activity via CCR1, CCR2 and CCR3 chemokine receptors: Implications as a potential therapeutic treatment of asthma.
|
24560857 |
2014 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocation.
|
24366869 |
2014 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocation.
|
24366869 |
2014 |